Disease control was experienced by 90% of patients with previously treated advanced clear cell renal cell carcinoma (ccRCC) who were treated with belzutifan (MK-6482) in combination with cabozantinib (Cabometyx), according to data from an ongoing phase 2 trial (NCT03634540).
Lead author Toni K. Choueiri, MD, presented early findings from a cohort of 52 patients treated with belzutifan, an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib at the 2021 Genitourinary Cancers Symposium. He cautioned that the results looked favorable but were very preliminary.1
“These preliminary, interim results for the combination of belzutifan and cabozantinib showed promising activity in previously treated metastatic clear cell RCC,” said Choueiri, director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI)/Brigham and Women’s Hospital…
